Researchers from Boston University School of Medicine and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration. The study, which appears ...
In is unacceptable to restrict the use of drugs for macular degeneration patients who have already lost their eyesight in one eye, according to an article in Drug and Therapeutics Bulletin (DTB), July 2007 issue. Full Story
This discovery suggests that the drugs may be helpful against dry macular degeneration, even though the virus does not cause that eye condition. The study, published in the scientific journal PNAS, found that people taking these HIV drugs had a significantly reduced risk of developing dry macular ...
Based on the seven-point dose response curve performed on CFH(Y/Y)-iRPE and CFH(H/H)-iRPE cells (Fig.6e, f), we selected the IC50dose for the two drugs (6 μM for L745 and 30 μM for ACA) to co-treat iRPE cells along with CC-HS. Immunostaining for p65 revealed reduced ...
Ophthalmologists in the US will soon have more options in their toolkit to manage neovascular age-related macular degeneration (AMD) and macular edema associated withuveitis. Susvimo, a 100 mg/mLranibizumabinjection for intravitreal use via ocular implant, has received FDA approval for wet AMD, and...
FOR OPHTHALMIC INTRAVITREAL INJECTION. Neovascular (Wet) Age-Related Macular Degeneration (AMD) LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days). Although not as effective, patients may be treated ...
Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions.
Age-related macular degeneration (AMD) is one of the main causes of visual impairment and severe visual loss, and can progress to two advanced forms—neovascularization and atrophic. The field of anti-AMD drugs has undergone huge developments in recent years, from single-target intravitreal administ...
Non-steroidal anti-inflammatory drugs for the prevention of macular edema after cataract surgery Objective To compare the preventive effectiveness of oral non-steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory eye drops on macular ed... G Wen,R Liao - 《Acta Universitatis Medicinal...
To date, one aptamer has been approved by the U.S. Food and Drug Administration, a drug for macular degeneration, a cause of blindness. Several others are being tested and developed for use in cardiovascular, hematology and cancer patients. ...